Stocks and Investing Stocks and Investing
Thu, February 23, 2023
Wed, February 22, 2023

Andrew Fein Reiterated (BCRX) at Strong Buy and Held Target at $30 on, Feb 22nd, 2023


Published on 2024-10-28 01:47:56 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy and Held Target at $30 on, Feb 22nd, 2023.

Andrew has made no other calls on BCRX in the last 4 months.



There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $13 on, Wednesday, November 2nd, 2022


This is the rating of the analyst that currently disagrees with Andrew


  • Liisa Bayko of "Evercore ISI Group" Upgraded from Hold to Buy and Held Target at $16 on, Wednesday, November 2nd, 2022